PharmaCielo (TSE:PCLO)
:PCLO
Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.04
<C$0.01(5.56%)
At close: 4:00 PM EST
C$0.04
<C$0.01(5.56%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
C$7.69M
Enterprise ValueC$28.70M
Total Cash (Recent Filing)C$289.24K
Total Debt (Recent Filing)C$18.65M
Price to Earnings (P/E)―
Beta-2.82
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding187,983,690
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Standardized Cannabinoid SupplyA clear B2B focus on producing standardized cannabinoid ingredients for medical and wellness customers establishes a durable business model. Supplying ingredient inputs to institutional manufacturers emphasizes repeatable demand, regulatory compliance needs, and scaleable manufacturing rather than volatile retail sales.
Positive Gross Margin On ProductsA roughly 29% gross margin indicates product-level economics that can support profitable operations if volumes recover. Positive unit margins provide scope for operating leverage, meaning sustained revenue growth could translate into meaningful improvement in overall profitability over several quarters.
Improving Cash Burn TrendOperating and free cash flow remain negative but the company reports materially smaller outflows versus earlier years, showing progress in reducing cash burn. This trend enhances near-term runway and lowers immediate refinancing pressure, improving the odds that operational improvements can be executed without urgent capital raises.
Bears Say
Declining Revenue TrendA 16.6% TTM revenue decline to about $2.6M signals weakening scale and demand. Continued top-line contraction undermines the company’s ability to absorb fixed costs, limits operational leverage, and makes it harder to convert positive unit economics into corporate profitability over the medium term.
Large Operating Losses PersistVery large negative EBIT and net margins show the business is not covering operating costs at current revenue levels. Persistent deep losses erode equity, necessitate external financing or restructuring, and constrain reinvestment in capacity or product development essential for sustainable growth.
Stressed Balance Sheet And LeverageSignificantly negative equity and debt materially above the asset base create solvency and refinancing risk. High leverage reduces financial flexibility, raises borrowing costs, and increases the probability of dilution or restructurings, limiting the company’s ability to invest for medium-term growth.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$7.69M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is May 04, 2026 which is in 5 days.
How were PharmaCielo’s earnings last quarter?
PharmaCielo released its earnings results on Mar 02, 2026. The company reported C$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.002.
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 187,983,690 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
PharmaCielo reported an EPS of C$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---